01653nas a2200565   4500000000100000000000100001000000100002008004100003653006300044653007100107653005600178653001200234653001100246653001200257653001200269653001100281653001000292653001600302653001100318653002200329653001100351653006100362653002400423653002100447653002000468653001800488653002500506653001800531653002400549100001700573700001600590700001600606700001100622700001700633700001600650700001700666700001300683700001000696700001500706700001300721700001300734700001400747700001400761700001600775245023300791250001501024300001001039490000701049020003101056       2021                            d10a*Cardiovascular Diseases/epidemiology/prevention & control10a*Diabetes Mellitus, Type 2/complications/drug therapy/epidemiology10a*Dipeptidyl-Peptidase IV Inhibitors/therapeutic use10aEngland10aFemale10aGermany10aGlucose10aHumans10aJapan10aMiddle Aged10aNorway10aRepublic of Korea10aSodium10a*Sodium-Glucose Transporter 2 Inhibitors/therapeutic use10aSweden/epidemiology10aDPP-IV inhibitor10aSGLT2 inhibitor10adapagliflozin10adiabetic nephropathy10aheart failure10aObservational study1 aK. Birkeland1 aJ. Bodegard1 aA. Banerjee1 aD. Kim1 aA. Norhammar1 aJ. Eriksson1 aM. Thuresson1 aS. Okami1 aK. Ha1 aN. Kossack1 aJ. Mamza1 aR. Zhang1 aT. Yajima1 aI. Komuro1 aT. Kadowaki00aLower cardiorenal risk with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study  a2020/09/08  a75-850 v23  a1462-8902 (Print)1462-8902